Wealth Architects LLC Has $472,000 Holdings in Cencora, Inc. $COR

Wealth Architects LLC lifted its holdings in Cencora, Inc. (NYSE:COR) by 14.2% during the 2nd quarter, HoldingsChannel reports. The fund owned 1,573 shares of the company’s stock after acquiring an additional 195 shares during the quarter. Wealth Architects LLC’s holdings in Cencora were worth $472,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of COR. GAMMA Investing LLC grew its stake in shares of Cencora by 57.0% in the first quarter. GAMMA Investing LLC now owns 5,748 shares of the company’s stock valued at $1,598,000 after acquiring an additional 2,087 shares in the last quarter. Integrated Advisors Network LLC acquired a new position in shares of Cencora in the first quarter valued at about $200,000. Simon Quick Advisors LLC grew its stake in shares of Cencora by 35.8% in the first quarter. Simon Quick Advisors LLC now owns 1,274 shares of the company’s stock valued at $354,000 after acquiring an additional 336 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Cencora by 0.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 273,522 shares of the company’s stock valued at $76,063,000 after acquiring an additional 1,884 shares in the last quarter. Finally, American Institute for Advanced Investment Management LLP acquired a new stake in Cencora during the first quarter worth about $4,068,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Jefferies Financial Group increased their price objective on shares of Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research note on Monday, June 30th. Wells Fargo & Company increased their price objective on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 13th. Morgan Stanley set a $330.00 price objective on shares of Cencora and gave the stock an “equal weight” rating in a research note on Wednesday, July 16th. Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Evercore ISI set a $340.00 price objective on shares of Cencora in a research note on Wednesday. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $320.00.

Insider Buying and Selling

In related news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This trade represents a 9.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction that occurred on Thursday, September 18th. The shares were sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the completion of the transaction, the chief executive officer owned 39,274 shares of the company’s stock, valued at approximately $11,389,460. This trade represents a 11.49% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 55,993 shares of company stock valued at $16,292,923. 10.80% of the stock is owned by company insiders.

Cencora Stock Up 1.2%

COR stock opened at $318.01 on Monday. The stock has a market capitalization of $61.66 billion, a P/E ratio of 32.72, a price-to-earnings-growth ratio of 1.49 and a beta of 0.63. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a 12 month low of $221.95 and a 12 month high of $319.68. The firm has a 50-day moving average price of $296.99 and a 200-day moving average price of $291.87.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.21. The firm had revenue of $80.66 billion during the quarter, compared to analysts’ expectations of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.34 earnings per share. As a group, equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora’s dividend payout ratio (DPR) is 22.63%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.